Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) generates news across respiratory support, blood monitoring, and emerging diagnostics, reflecting its role as a commercial-stage medical device company. Company announcements highlight the FDA-cleared INSPIRA ART100 cardiopulmonary support system, the development of the INSPIRA ART500 oxygenation platform, and progress with the HYLA non-invasive blood sensor, including completion of a clinical study and preparation for regulatory submission.
News coverage also follows Inspira’s strategic move into liquid biopsy diagnostics. The company has outlined a non-binding term sheet and proposed transaction to acquire an advanced liquid biopsy platform focused initially on breast cancer and circulating tumor cell analysis, alongside a concurrent equity investment and a contingent value rights framework for existing shareholders. These updates provide insight into how Inspira aims to extend its expertise in blood-based technologies into oncology diagnostics.
Investors and observers can expect IINN news to include regulatory milestones, such as submissions and anticipated approvals in markets like the United Arab Emirates, as well as updates on binding purchase orders, deployment timelines, and collaborations. Recent items have covered a registered direct offering, a Standby Equity Purchase Agreement, expansion of laboratory infrastructure, and an AI-based training alliance with Bites Learning Ltd. Leadership appointments and shareholder meeting notices also appear in the company’s news flow.
This news page aggregates these developments in one place, helping readers follow Inspira’s clinical, regulatory, commercial, and corporate updates over time.
Inspira Technologies has established a strategic collaboration with Westchester Medical Center in New York to evaluate the performance of its FDA-cleared INSPIRA ART100 systems in clinical scenarios. The partnership aims to expose Inspira's technology to leading physicians and medical institutions.
The collaboration includes plans to explore future deployment of Inspira's next-generation flagship technology, the INSPIRA ART system, currently in development. This system is designed to treat acute respiratory failure by elevating declining oxygen saturation levels without mechanical ventilators.
Westchester Medical Center, as one of few centers in New York State performing Cardiopulmonary Bypass and Extracorporeal Membrane Oxygenation, will integrate this technology to enhance treatment of acute respiratory failure.
Inspira Technologies (NASDAQ: IINN) announces an upcoming live investor webinar and Q&A session scheduled for November 11, 2024, at 4:15 p.m. EST. The event, hosted by RedChip Companies, will feature company President Joe Hayon discussing innovative life support technology developments. The presentation will focus on their technology designed to monitor and improve declining blood oxygen saturation levels without mechanical ventilation, potentially disrupting the $19 billion mechanical ventilation market. Investors can register for free and submit questions in advance or during the event.
Inspira Technologies (Nasdaq: IINN) has signed a distribution agreement with Glo-Med Networks to serve as its primary distributor in the United States. The agreement establishes a Florida-based distribution facility that will support the deployment of the INSPIRA ART100, which is FDA 510(k)-cleared for Cardiopulmonary Bypass procedures. The facility will provide customer support and after-market services through a partnership with Med-Stat Consulting Services. This strategic move aims to enhance operational efficiency for the planned 2024 deployment of the ART100 and future products. The company's flagship product, INSPIRA ART, targets a potential $19 billion market opportunity, aiming to serve 20 million acute respiratory failure patients annually.
Inspira Technologies (Nasdaq: IINN) has announced a partnership with Glo-Med Networks as its primary U.S. distributor for the INSPIRA ART100 device, which is FDA 510(k)-cleared for Cardiopulmonary Bypass procedures. The distribution facility, located in Florida, will support deployment and maintenance of the system, with Med-Stat Consulting Services providing certified after-market services.
The company's proprietary INSPIRA ART device aims to revolutionize life support for acute respiratory failure patients, targeting a potential $19 billion market opportunity with 20 million annual patients. The technology is designed to monitor and elevate declining blood saturation levels without requiring a mechanical ventilator, with planned deployment beginning in 2024.
Inspira Technologies (Nasdaq: IINN) has announced the development of a new disposable kit for the perfusion market. This innovation is part of Inspira's strategy to generate recurring revenues and potentially tap into the $1 billion perfusion systems market. The single-use kit is designed to identify and alert users on performance changes during operation and treatment, aiming to enhance product safety and patient protection.
The disposable kit will be subject to an FDA clearance application and is expected to be offered to hospitals using the INSPIRA ART100 system. The ART100 system received FDA 510(k) clearance for Cardiopulmonary Bypass procedures in May 2024 and Israeli certification for extra-corporeal membrane oxygenation and cardiopulmonary bypass procedures in July 2024. The first manufactured devices are expected to be deployed in the U.S. by the end of 2024.
Inspira™ Technologies OXY B.H.N. (Nasdaq: IINN, IINNW) is set to showcase its latest innovations at the 34th Annual Extracorporeal Life Support Organization (ELSO) Conference in Detroit, Michigan, from September 29-30, 2024. The company will present its FDA-cleared INSPIRA™ ART100 system, which is ready for deployment in the U.S. market.
Attendees will have the opportunity to experience interactive demonstrations and presentations of Inspira's technologies. The company's U.S. sales team, led by chief distributor Glo-Med Networks Inc., will be present at booth #18 to discuss the potential impact of these innovations on patient care. Key personnel, including VP of Product Tomer Carmeli, Medical Director Dr. Dekel Stavi, and CTO Dr. Daniella Yeheskely-Hayon, will be available to address questions and showcase the INSPIRA™ ART100 system's features and advantages.
Inspira™ Technologies (Nasdaq: IINN) has secured a second U.S. Patent approval for its VORTX™ orbiting blood oxygenation delivery system, a core technology of the INSPIRA™ ART device. This brings the total novel claims for the core technology to 32. The VORTX™ system aims to oxygenate blood without fiber membranes, potentially reducing blood damage and costs compared to current technologies.
The INSPIRA™ ART device targets the $19 billion mechanical ventilation market, offering a potential alternative for the 20 million ICU patients with respiratory failure annually. It aims to maintain stable oxygen saturation levels without ventilators, allowing patients to remain awake during treatment.
Inspira™ Technologies has developed Augmented Respiration Technology (INSPIRA™ ART) with adaptive blood monitoring. The INSPIRA™ ART100 system has obtained FDA 510(k) clearance for Cardiopulmonary Bypass procedures and Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.
Inspira Technologies (Nasdaq: IINN) has announced plans to report clinical results for its HYLA™ blood sensor in Q4 2024. The clip-on sensor aims to alert physicians of changes in a patient's condition without intermittent blood samples, targeting a potential $2.5 billion Point of Care testing and Arterial Blood Gas analyzer market. Inspira is expanding its blood testing facilities to accelerate HYLA™ development, with a 510(k) submission to the FDA planned for early 2025.
The company's broader strategy involves transforming respiratory and life-support sectors, addressing an estimated $59 billion annual market opportunity. Inspira plans to deploy its FDA-cleared INSPIRA™ ART100 system in top U.S. and Israeli hospitals. The company is also developing additional products, including the INSPIRA™ ART (Gen 2) and INSPIRA™ Cardi-ART, focusing on innovative oxygenation and blood monitoring technologies.
Inspira Technologies OXY B.H.N. (IINN) has announced the FDA listing of its INSPIRA™ CART, a medical cart designed for use with the INSPIRA™ ART100 system. This Class I Medical Device, 510(K) Exempt, is intended for use in operating rooms during Cardiopulmonary Bypass procedures. The company aims to streamline healthcare delivery and transform the ART100 system into a mobile workstation.
Inspira is developing novel life support-extending technologies, targeting a combined market opportunity of approximately $59 billion annually. The company's product pipeline includes the HYLA™ blood sensor, INSPIRA™ Cardi-ART, and INSPIRA™ ART (Gen 2). These technologies are designed to monitor blood parameters, support cardiac arrest patients, and provide adaptive blood oxygenation, respectively.
Inspira Technologies (Nasdaq: IINN) has announced that a leading medical technology company approached them to evaluate the operation of their key product in combination with the INSPIRA™ ART100 system. The evaluation, conducted by Inspira researchers, showed that test results exceeded 100% of the standard value for gas transfer at maximum flow when integrated with the ART100 system.
The tests were performed in Inspira's advanced laboratory, simulating oxygen-deficient and carbon dioxide-rich blood conditions. The successful results demonstrate the power and versatility of the INSPIRA™ ART100 system in various technology settings. Inspira believes this validates the system's compatibility and performance with key products of a leading medical technology company, potentially leading to meaningful business development activities.